Utilizing the Hippo pathway as a therapeutic target for combating endocrine-resistant breast cancer

Table 1 Targeted agents approved for combination with endocrine therapy for the treatment of breast cancer

Targets	Agents	Mechanism	References
mTOR	Everolimus	Generates a complex that inhibits the activation of mTOR	[7]
CDK4/6	Palbociclib	Inhibits CDK4/6, allowing restoration of control of cell cycle	[8]
	Ribociclib		[9]
	Abemaciclib		[10]
PI3K	Alpelisib	Specifically inhibits PI3Kα	[11]

CDK cyclin-dependent kinase, mTOR mammalian target of rapamycin, PI3K phosphoinositide 3-kinase

ISSN: 1475-2867